S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Part of paid clinical trials in San Antonio, Texas.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00016094
Phase
PHASE2
Status
Completed

Conditions

  • Anaplastic Large Cell Lymphoma
  • Recurrent Adult Burkitt Lymphoma
  • Recurrent Adult Diffuse Large Cell Lymphoma
  • Recurrent Mantle Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
    Given IV
  • laboratory biomarker analysis — OTHER
    Correlative studies

Study Details

Phase II trial to study the effectiveness of bevacizumab in treating patients who have non-Hodgkin's lymphoma. Monoclonal antibodies such as bevacizumab may stop the growth of cancer by stopping blood flow to the tumor. Bevacizumab may be an effective treatment for non-Hodgkin's lymphoma

Key Dates

First listed
Jan 27, 2003
Start date
Apr 30, 2001
Status verified
Jan 2013
Primary completion
Aug 31, 2005
Completion
Sep 30, 2008

Study Design

Enrollment
60 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (bevacizumab)
    Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Progression-free survival rate in patients treated with single agent bevacizumab [ Time Frame: Date of registration to date of first observation of progressive disease, or death due to any cause, assessed up to 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Southwest Oncology GroupSan AntonioTexas78245-

Find similar trials in San Antonio, TX

By research site
Southwest Oncology Group· San Antonio, TX

Related Studies